News >

Spigel Reflects on Recent Immunotherapy Success in Stage III NSCLC

Angelica Welch
Published: Friday, Mar 02, 2018

Dr. David Spigel

David Spigel, MD
It is estimated that one-quarter of patients with non–small cell lung cancer (NSCLC) will present with stage III disease at diagnosis, but the population rarely receives attention in the clinical trial space, says David R. Spigel, MD.

There is a vested interest in combinations with nivolumab (Opdivo) and ipilimumab (Yervoy), and IDO inhibitors with pembrolizumab (Keytruda) and nivolumab. Spigel said that these trials will be difficult to conduct going forward because not many in the community are convinced anything will show superiority compared with durvalumab.


  1. Paz-Ares L, Villegas A, Daniel D, et al. PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC. In: Proceedings from the 2017 ESMO Congress; September 9-12, 2017; Madrid, Spain. Abstract LBA1_PR.
  2. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017; 377:1919-1929. doi: 10.1056/NEJMoa1709937.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication